My career has been dedicated to the investigation and development of RNA-based therapeutic approaches (including RNA aptamers, siRNAs, mRNA, RNA editing oligonucleotides) for cancer, cardiovascular disease, rare diseases, and critical illness. As a consequence, I have developed a deep understanding of these technologies, diseases, and associated disease mechanisms. I am an internationally recognized expert in oligonucleotide therapeutics and delivery. Towards this end, I was the first to demonstrate that RNA ligands (aptamers) can be used to deliver therapeutic siRNAs to target cells in vivo. My 80+ publications and 9+ patents are a testament to this body of work and my commitment to the development of novel RNA-based therapies for many diseases. I value teamwork and problem solving. I see mentoring/inspiring the next generation of scientists, educating the lay community, and working closely with academia, industry, and regulatory agencies as essential to advancing transformative drugs for patients.